Shares of CalciMedica (CALC) tumbled 14.9% to $0.50 on August 27, 2026, after the clinical-stage biotech announced a one-for-five reverse stock split — a move that consolidates every five shares into one — designed to lift its price above Nasdaq's $1.00 minimum bid requirement and avoid delisting. CalciMedica Slashes Its Share Count to Stay on Nasdaq — but Does a Reverse Split Fix What Ails a Cash-Strapped Biotech?
Shares of CalciMedica plunged 14.9% to $0.50 as the clinical-stage drugmaker announced a one-for-five reverse stock split — consolidating every five shares into one — to push its price above Nasdaq's $1.00 minimum and avoid being kicked off the exchange. The split takes effect after market close on August 28, with adjusted trading beginning August 31. For a 16-person company with no revenue and no approved drugs, the move raises an uncomfortable question: does financial engineering buy enough time for the science to pay off?
• The Listing Threat Is Real, and the Fix Is Cosmetic. Shareholders approved the reverse split at a ratio ranging from 1-for-2 to 1-for-10, leaving the final ratio to the board's discretion. Management chose 1-for-5, which will shrink outstanding shares from roughly 34.5 million to 6.9 million and mechanically lift the price near $2.50. But the company's market capitalization — around $17 million — stays the same. Nothing about the business changes; the stock just gets repackaged.
• A Discontinued Trial and a Pivot to Lung Disease Define the Road Ahead. In January 2026, CalciMedica discontinued its Phase 2 kidney-injury trial after an independent safety monitoring committee recommended stopping. The company has since pivoted: it plans a Phase 1b trial of its lead drug in patients with pulmonary arterial hypertension, a deadly lung condition, with data expected in mid-2027. A second compound targeting the same disease area is expected to enter human testing via an FDA application in mid-2027.
• A $49 Million Financing Provides a Lifeline — With Strings Attached. In June, CalciMedica announced a private placement raising up to $49 million in gross proceeds, including roughly $15 million upfront.
The company says the cash extends its runway into the second half of 2027. But outstanding warrants already reserve over 45.7 million shares for potential issuance , meaning heavy dilution looms if those warrants are exercised — even after the reverse split shrinks today's share count.
• Wall Street Is Conflicted. Two analysts rate the stock a Buy with an average 12-month price target of $10.50 , implying enormous upside. Yet the stock has cratered 93% from its 52-week high of $7.20. The company generates no revenue, continues burning cash, and carries negative equity on its balance sheet. Until mid-2027 trial data arrive, shareholders are betting on promise alone — now with fewer shares in their accounts.